BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 20, 2009
View Archived Issues
4SC commences phase II 4SC-201 trial in hepatocellular carcinoma
Read More
Sitaxsentan treatment has multiple benefits in chronic kidney disease
Read More
Pfizer develops novel irreversible and reversible SARS 3CL protease inhibitors
Read More
Tumor hypoxia marker [18F]HX4 safe in phase I trial, phase II study planned
Read More
Novavax reports preclinical results from ferret study of H1N1 influenza VLP vaccine
Read More
Lpath completes enrollment in phase I study of iSonep in wet AMD
Read More
Roche reports results for first half 2009
Read More
GlaxoSmithKline claims tricyclic nitrogen-containing compounds as antibacterials
Read More
Array BioPharma describes Akt protein kinase inhibitors for cancer
Read More
Cathepsin K inhibitors identified at Amura for treating bone disorders
Read More
Solvay discloses bifeprunox derivatives for PD and other CNS-related disorders
Read More
LXR ligands for a variety of potential applications described by Wyeth
Read More
Abbott discloses new calpain inhibitors for neurological and other disorders
Read More
Focus of gamma-secretase inhibitor PF-3084014 shifts to cancer
Read More
Bristol-Myers Squibb identifies potent corticotropin-releasing factor-1 receptor antagonist
Read More
Light Sciences Oncology treats patients in phase II Aptocine trial in BPH
Read More
Peplin completes enrollment in final phase III ingenol mebutate trial in AK
Read More
COTI-2 plus Doxil superior to Doxil alone in animal ovarian cancer model
Read More
Amira submits IND for AM-461
Read More
Ablynx reports phase I results for subcutaneous administration of ALX-0681
Read More
Forest reports phase IIb results for oglemilast in COPD
Read More
Pfizer targets the type 1 glycine transporter with PF-3463275 for schizophrenia
Read More
Severe lung damage linked to long-term occupational nanoparticle exposure
Read More
InterMune and Roche initiate dosing in phase IIb clinical trial of ITMN-191
Read More
Gentium reports results from phase III defibrotide trial for sVOD
Read More